Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified)

Catalog # LI2-H5253

Synonym

LILRB2,ILT4,LIR2,MIR10,CD85d

Source

Human LILRB2, Fc Tag(LI2-H5253) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Val 461 (Accession # AAH36827.1). Predicted N-terminus: Gln 22

Molecular Characterization

LILRB2(Gln 22 - Val 461) AAH36827.1	Fc(Pro 100 - Lys 330) P01857

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 74.2 kDa. The protein migrates as 95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human LILRB2, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS



The purity of Human LILRB2, Fc Tag (Cat. No. LI2-H5253) is more than 95% and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.
Report

Bioactivity-ELISA



Immobilized Human LILRB2, Fc Tag (Cat. No. LI2-H5253) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).



Serial dilutions of Monoclonal Anti-LILRB2 Antibody, Human IgG1 were added into Human LILRB2, Fc Tag (Cat. No. LI2-H5253) : Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein, His,Avitag (Cat. No. HLG-H52E9) binding reactions. The half maximal inhibitory concentration (IC50) is 0.70 μg/mL (Routinely tested).



Immobilized Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Cat. No. HLM-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human LILRB2, Fc Tag (Cat. No. LI2-H5253) with a linear range of 0.6-10 ng/mL (Routinely tested).

Background

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates